Gene info: ID 9965

Gene: FGF19

GENE ID: 9965

Synonyms: -

Description: fibroblast growth factor 19

Gene type: protein-coding

Location: 11q13.3

dbXrefs: Ensembl:ENSG00000162344 MIM:603891 Vega:OTTHUMG00000167886 UniprotKB:O95750

RefSeq: NC_000011.10

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 3

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.389e-1 (AD) 3.034e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MUC17	0.786
DUXA	0.784
MMP13	0.781
TAAR1	0.778
TAS2R60	0.764
OR52K1	0.757
CPN2	0.755
OR2W5	0.749
INSL4	0.747
C18orf63	0.742

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
FUT9	-0.239
CABLES1	-0.217
CDH20	-0.21
ERBB4	-0.208
NDP	-0.207
OMG	-0.202
LYPD6	-0.201
SLC6A1	-0.193
ACSS1	-0.189
LRTOMT	-0.189

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01109	Heparin	Small Molecule	9005-49-6	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
D016604	Aflatoxin B1	Aflatoxin B1 results in increased methylation of FGF19 gene	27153756
D001151	Arsenic	Arsenic affects the expression of FGF19 protein	24675094
D001647	Bile Acids and Salts	FGF19 protein affects the chemical synthesis of and affects the secretion of and affects the uptake of Bile Acids and Salts	22268002
D001647	Bile Acids and Salts	FGF19 protein affects the chemical synthesis of and affects the secretion of and affects the uptake of Bile Acids and Salts	22268002
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of FGF19 mRNA	26894911
C006780	bisphenol A	bisphenol A results in increased methylation of FGF19 promoter	27271280
C006780	bisphenol A	bisphenol A results in decreased expression of FGF19 mRNA	25181051
C584509	C646 compound	C646 compound results in increased expression of FGF19 mRNA	26191083
D002635	Chenodeoxycholic Acid	[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter	22561792
D002635	Chenodeoxycholic Acid	[[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA	22561792\|2256179
D002635	Chenodeoxycholic Acid	Chenodeoxycholic Acid results in increased expression of FGF19 mRNA	16269825\|1769625
D002635	Chenodeoxycholic Acid	Chenodeoxycholic Acid results in increased expression of FGF19 protein	20835427
D002635	Chenodeoxycholic Acid	[Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein	20835427
D019826	Cholic Acid	[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter	22561792
D019826	Cholic Acid	[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA	22561792\|2256179
D019826	Cholic Acid	Cholic Acid results in increased expression of FGF19 mRNA	25055961
C010902	decabromobiphenyl ether	decabromobiphenyl ether analog results in decreased expression of FGF19 mRNA	26854739
D003840	Deoxycholic Acid	[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter	22561792
D003840	Deoxycholic Acid	[[Deoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA	22561792\|2256179
D003840	Deoxycholic Acid	Deoxycholic Acid results in increased expression of FGF19	22268002
D003840	Deoxycholic Acid	Deoxycholic Acid results in increased expression of FGF19 mRNA	25055961
C118739	entinostat	entinostat results in increased expression of FGF19 mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
C579439	epiallopregnanolone sulfate	epiallopregnanolone sulfate inhibits the reaction [GW 4064 results in increased expression of FGF19 mRNA]	22961653
C579439	epiallopregnanolone sulfate	epiallopregnanolone sulfate inhibits the reaction [GW 4064 results in increased expression of FGF19 protein]	22961653
D005230	Fatty Acids, Nonesterified	"FGF19 protein affects the reaction [NR1H4 protein affects the abundance of Fatty Acids, Nonesterified]"	22130247
D005230	Fatty Acids, Nonesterified	"FGF19 protein results in decreased abundance of Fatty Acids, Nonesterified"	22130247
D006002	Glycodeoxycholic Acid	Glycodeoxycholic Acid results in decreased expression of FGF19 mRNA	24994853
D006002	Glycodeoxycholic Acid	Glycodeoxycholic Acid results in decreased expression of FGF19 protein	24994853
C412815	GW 4064	[GW 4064 results in increased activity of NR1H4 protein] which binds to FGF19 promoter	22561792
C412815	GW 4064	[[GW 4064 results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA	22561792\|2256179
C412815	GW 4064	GW 4064 results in increased expression of FGF19 mRNA	16269825
C412815	GW 4064	epiallopregnanolone sulfate inhibits the reaction [GW 4064 results in increased expression of FGF19 mRNA]	22961653
C412815	GW 4064	epiallopregnanolone sulfate inhibits the reaction [GW 4064 results in increased expression of FGF19 protein]	22961653
C412815	GW 4064	GW 4064 results in increased expression of FGF19 mRNA	22961653
C412815	GW 4064	GW 4064 results in increased expression of FGF19 protein	22961653
D006493	Heparin	Heparin binds to FGF19 protein	14730967
D006493	Heparin	Heparin promotes the reaction [FGF19 protein binds to FGFR4 protein]	10525310
C492448	ICG 001	ICG 001 results in increased expression of FGF19 mRNA	26191083
C011582	IMOL S-140	IMOL S-140 results in increased expression of FGF19 mRNA	26894911
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of FGF19 mRNA	26752646
D008095	Lithocholic Acid	[Lithocholic Acid results in increased activity of NR1H4 protein] which results in increased expression of FGF19 mRNA	22561792
D008095	Lithocholic Acid	[Lithocholic Acid results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA	22561792
D008095	Lithocholic Acid	Lithocholic Acid results in increased expression of FGF19 mRNA	17696253\|2505596
D008095	Lithocholic Acid	NR1I2 protein promotes the reaction [Lithocholic Acid results in increased expression of FGF19 mRNA]	17696253
D008727	Methotrexate	Methotrexate results in decreased expression of FGF19 mRNA	17400583
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of FGF19 mRNA	24810058
C464660	obeticholic acid	obeticholic acid results in increased expression of FGF19 mRNA	27939613
C464660	obeticholic acid	obeticholic acid results in increased secretion of FGF19 protein	27939613
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF19 mRNA"	27188386
C496932	panobinostat	panobinostat results in increased expression of FGF19 mRNA	26272509
C101814	perfluoro-n-undecanoic acid	perfluoro-n-undecanoic acid results in increased expression of FGF19 mRNA	23602845
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of CYP17A1 mRNA]	16269825
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of PON1 mRNA]	16269825
D012293	Rifampin	[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA	17696253
D012293	Rifampin	Rifampin results in increased expression of FGF19 mRNA	17696253
D019438	Ritonavir	Ritonavir results in increased expression of FGF19 mRNA	26626330
C017947	sodium arsenite	sodium arsenite results in increased expression of FGF19 mRNA	25879800
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of FGF19 mRNA	26854739
C582340	tetradecabromodiphenoxybenzene	tetradecabromodiphenoxybenzene analog results in decreased expression of FGF19 mRNA	26854739
D014212	Tretinoin	Tretinoin results in increased expression of FGF19 mRNA	21274875
D014212	Tretinoin	Ursodeoxycholic Acid promotes the reaction [Tretinoin results in increased expression of FGF19 mRNA]	21274875
D014280	Triglycerides	FGF19 protein affects the reaction [NR1H4 protein affects the abundance of Triglycerides]	22130247
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid promotes the reaction [Tretinoin results in increased expression of FGF19 mRNA]	21274875
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid results in increased expression of FGF19 mRNA	25055961
D014635	Valproic Acid	Valproic Acid affects the expression of FGF19 mRNA	25979313

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005088	Ras guanyl-nucleotide exchange factor activity	-	TAS	-
GO:0005104	fibroblast growth factor receptor binding	-	IPI	10525310 17627937
GO:0005515	protein binding	-	IPI	18829467
GO:0008083	growth factor activity	-	IEA	-
GO:0016303	1-phosphatidylinositol-3-kinase activity	-	TAS	-
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	TAS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000165	MAPK cascade	-	TAS	-
GO:0001755	neural crest cell migration	-	IEA	-
GO:0001934	positive regulation of protein phosphorylation	-	IDA	17627937
GO:0007399	nervous system development	-	TAS	9931477
GO:0007507	heart development	-	IEA	-
GO:0008284	positive regulation of cell proliferation	-	IGI	18187602
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IGI	18187602
GO:0008543	fibroblast growth factor receptor signaling pathway	-	IPI	10525310
GO:0008543	fibroblast growth factor receptor signaling pathway	-	TAS	-
GO:0010469	regulation of signaling receptor activity	-	IEA	-
GO:0010629	negative regulation of gene expression	-	IDA	19085950
GO:0036092	phosphatidylinositol-3-phosphate biosynthetic process	-	IEA	-
GO:0046326	positive regulation of glucose import	-	IDA	17623664
GO:0046330	positive regulation of JNK cascade	-	IDA	12815072
GO:0046854	phosphatidylinositol phosphorylation	-	IEA	-
GO:0051897	positive regulation of protein kinase B signaling	-	TAS	-
GO:0070374	positive regulation of ERK1 and ERK2 cascade	-	IDA	17623664 19085950
GO:0070858	negative regulation of bile acid biosynthetic process	-	IDA	12815072

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	TAS	-
GO:0005622	intracellular	-	IEA	-

KEGG ID	KEGG Term
hsa04010	MAPK signaling pathway
hsa04810	Regulation of actin cytoskeleton
hsa05200	Pathways in cancer
hsa05218	Melanoma

Reactome ID	Reactome Term	Evidence
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1307965	betaKlotho-mediated ligand binding	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-190322	FGFR4 ligand binding and activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-5654228	Phospholipase C-mediated cascade; FGFR4	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
26943773	Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. (2016 Apr 5)	Tan Q	Oncotarget
28906590	FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas. (2017 Nov)	Zhang X	Thorac Cancer
22074045	The FGF and FGFR Gene Family and Risk of Cleft Lip With or Without Cleft Palate. (2013 Jan)	Wang H	Cleft Palate Craniofac J